MALIGNANT MELANOMA
Clinical trials for MALIGNANT MELANOMA explained in plain language.
Never miss a new study
Get alerted when new MALIGNANT MELANOMA trials appear
Sign up with your email to follow new studies for MALIGNANT MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New vaccine combo aims to boost Body's fight against advanced skin cancer
Disease control OngoingThis study is testing whether adding one of two experimental cancer vaccines (SCIB1 or iSCIB1+) to standard immunotherapy drugs can help people with advanced, inoperable melanoma. The goal is to see if the vaccines make the standard treatments work better and longer for patients.…
Matched conditions: MALIGNANT MELANOMA
Phase: PHASE2 • Sponsor: Scancell Ltd • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New oral combo aims to boost melanoma treatment power
Disease control OngoingThis study is testing whether adding an oral drug called DEC-C to standard immunotherapy (nivolumab) can make treatment more effective for people with advanced mucosal melanoma. The goal is to see if this combination can better activate the immune system against the cancer. The t…
Matched conditions: MALIGNANT MELANOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
New drug combo tested in kids fighting aggressive skin cancer
Disease control OngoingThis study tested a combination of two drugs, temozolomide and peginterferon, to see how well they work in children with high-risk or advanced melanoma. The goal was to see if the treatment could shrink tumors and prevent the cancer from coming back. Children were placed in diffe…
Matched conditions: MALIGNANT MELANOMA
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
First patients test new pfizer cancer drug in early safety trial
Disease control OngoingThis is an early-stage study to test the safety and initial effects of a new drug called PF-08046037. It is being tested alone and in combination with another immunotherapy drug (sasanlimab) in people with advanced or spreading cancers, including lung, head and neck, skin, and pa…
Matched conditions: MALIGNANT MELANOMA
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC